Evotec AG
EVO Healthcare Drug Manufacturers Specialty & Generic
Evotec AG’s revenue for fiscal 2025 (year ended December 2025) was $892.0 million, up 3.43% from fiscal 2024. In the quarter to June 2026, revenue fell 13.0%, EPS fell 328.9%, free cash flow fell 9,727.2% and total debt rose 5.48%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow EVO
Evotec AG (EVO) EV/Sales
As of 16 October 2026, Evotec AG (EVO) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from 0.6× (October 2026) to 16.4× (October 2017); the current reading is higher than 0% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.2× | (37.31%) |
| FY2024 | 1.9× | (55.58%) |
| FY2023 | 4.3× | 28.25% |
| FY2022 | 3.3× | (67.39%) |
| FY2021 | 10.2× | 3.81% |
| FY2020 | 9.9× | 23.40% |
| FY2019 | 8.0× | 22.30% |
| FY2018 | 6.5× | (23.53%) |
| FY2017 | 8.5× | 60.13% |
| FY2016 | 5.3× | 60.17% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 1.0× | (18.89%) |
| Dec 2025 | 1.2× | (37.47%) |
| Sep 2025 | 1.9× | (0.73%) |
| Jun 2025 | 1.9× | 15.82% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLRY Tilray Brands, Inc. compare | 0.6× |
| EVO Evotec AG | 0.6× |
| EBS Emergent Biosolutions Inc. compare | 1.0× |
| KMDA Kamada Ltd. compare | 2.1× |
| EOLS Evolus, Inc. compare | 2.1× |
| COLL Collegium Pharmaceutical, Inc. compare | 2.1× |
| IRWD Ironwood Pharmaceuticals, Inc. compare | 2.8× |
| AQST Aquestive Therapeutics, Inc. compare | 7.9× |
| TKNO Alpha Teknova, Inc. compare | 8.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)